Encompass Health Beat Q2 and Raised Guidance-So Is the Stock Really Cheap Now?

EHC's earnings beat was clear, but the stock debate now shifts to execution

Encompass Health delivered a clean second-quarter beat. After the 13.2% jump, with Q2 revenue up 9.6% and adjusted EPS up 10.7%, the market's first reaction was to reward the headline.

Why the move is not the same as a finished thesis

The harder question is whether the stock has already priced in the good news and now needs steady follow-through. Management also raised its full-year view to adjusted EPS of $6.02 to $6.25, which is slightly above the roughly $6.00 Street estimate. That is a supportive update, not an outsized surprise, and it supports a higher valuation mainly if operations keep improving.

Analyst behavior reflects that split. Wall Street still sits at a "Moderate Buy" consensus with an average target of $146.57, but Wall Street Zen recently downgraded the stock to "Hold." The broad view is still constructive, even if some investors now see the narrative shifting from a strong quarter to a higher bar for the next one.

This quarter mattered because it did more than beat near-term numbers; it made the demand case more concrete.

Encompass Health's occupancy and expansion plan make demand tangible

Occupancy shows current demand is holding up

The clearest signal is occupancy reached 77.4%, up 290 basis points year over year. That matters because it suggests patient demand is filling the capacity Encompass already has in place, not just supporting one quarter of revenue growth.

Expansion is the next test of that demand

That demand story is now tied to capacity growth. Encompass plans five more hospitals and 100–150 additional beds for the rest of 2026. The company also pointed to a longer cadence of six to 10 new facilities annually beginning in 2029. If demand stays firm, that added supply can support future earnings. If demand weakens, the same plan raises ramp, staffing, and margin risk.

Valuation now depends on execution, not just the headline beat

The raised guide moves the discussion from results to execution. Encompass now expects $6.41 billion–$6.49 billion in revenue and adjusted EPS of $6.02–$6.25. That gives investors a reason to be constructive, but it also means the market will want to see capacity additions translate cleanly into revenue and margins.

There is also at least one strategic tailwind worth watching. Encompass has shifted its Medicare Advantage payer mix from approximately 9.2% in 2018 to around 16.5% by Q1 2025. Still, a more favorable mix does not eliminate execution risk. Construction costs, labor availability, and slower-than-expected maturation at newer sites can still pressure the story.

What to watch next

The next few quarters should clarify whether the rerating still has room. The key signals are:

• Occupancy trends: whether the 77.4% level holds or improves as new beds come online.
• New facility ramps: whether recent and planned openings produce the expected volume and margin contribution.
• Full-year guide attainment: whether the company can deliver on adjusted EPS of $6.02 to $6.25.
• Payer mix: whether the shift toward around 16.5% by Q1 2025 Medicare Advantage continues.
• Expansion pacing: whether the plan for six to 10 new facilities annually beginning in 2029 remains aligned with demand and staffing capacity.